Advertisement
UK markets close in 7 hours 40 minutes
  • FTSE 100

    7,825.87
    -51.18 (-0.65%)
     
  • FTSE 250

    19,277.05
    -173.62 (-0.89%)
     
  • AIM

    741.39
    -3.90 (-0.52%)
     
  • GBP/EUR

    1.1682
    -0.0001 (-0.01%)
     
  • GBP/USD

    1.2447
    +0.0008 (+0.07%)
     
  • Bitcoin GBP

    51,845.48
    +2,685.50 (+5.46%)
     
  • CMC Crypto 200

    1,326.98
    +14.36 (+1.10%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CRUDE OIL

    83.86
    +1.13 (+1.37%)
     
  • GOLD FUTURES

    2,403.70
    +5.70 (+0.24%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • HANG SENG

    16,226.37
    -159.50 (-0.97%)
     
  • DAX

    17,635.37
    -202.03 (-1.13%)
     
  • CAC 40

    7,951.83
    -71.43 (-0.89%)
     

Is OrganiGram a Buy After Its Improved Q3 Results?

Is OrganiGram a Buy After Its Improved Q3 Results?

Canadian cannabis company OrganiGram Holdings (NASDAQ: OGI) hasn't been a great growth investment over the past year. OrganiGram highlighted impressive quarter-over-quarter revenue growth of 51% when it reported its third-quarter results. Net revenue of CA$20.3 million was up by 39% from the previous quarter.